Parkinson’s disease (PD) is a nervous disorder, which affects movement and the ability for the same of an individual. In the initial stage of Parkinson’s,
one may experience lessening expressions on the face and swinging of hands while walking. The symptoms of this disease worsen as the condition progresses
over time. Parkinson’s disease has been tagged as the 14th leading cause of death in the U.S., where around 50,000-60,000 new cases of PD are diagnosed
each year. There are already more than 1 million patients of PD in the country, a significant part of the approximately 6 million patients of PD across the
The exact factors behind Parkinson’s condition are not very clear. However, researchers and scientists are striving to find a cure for this condition and
several therapeutic methods are in their developmental stages. Due to the tremendous research activities undertaken on a global level and technological
advancements in the medicine industry, knowledge about the procedures involved in neurodegeneration has expanded. Also, knowledge regarding the
neuroanatomy of basal ganglia, which is an important factor for determining the causes of PD, is now highly developed.
PD Pipeline Bears 90 First-In-Class Products, Providing Scope for Growth
In the present scenario, the Parkinson’s disease pipeline consists of 302 products in different developmental stages, including 90 first-in-class
therapies. The products in the pipeline are very much different from the ones available in the market currently. The employed PD products target
neuromodulatory receptors, whereas the ones in the pipeline comprise various neuroprotective therapies, which will be targeting dysfunctional disease
Since 2006, many PD therapeutics have been brought into the research arena; however, only 9 of them have been developed till date. This figure proves that
there are huge growth opportunities for the market players in the Parkinson’s disease therapeutics market. Constant innovation is one of the major
factors that are expected to help market players enjoy the competitive edge in the extremely fragmented Parkinson’s disease therapeutics market in the near
Huge Variety of Pipeline Products to Generate Huge Opportunities for Market Players
Some of the PD pipeline programs focus on the some of the factors such as cerebral dopamine neurotrophic factor, heat shock transcription factor,
cytochrome P450 2D6, DJ-1, tyrosine receptor kinase B, metabotropic glutamate receptor, heat shock proteins, progranulin, growth hormone secretagogue
receptor, reactive oxygen species, C-jun-N-terminal kinases, glial cell-derived neurotrophic factor, protein phosphasate 2A, LRRK2, and mesencephalic
astrocyte-derived neurotrophic factor.
The wide range in the products is due to the presence of 90 first-in-class therapies, which account for approximately 37% of the overall therapeutics in
the PD pipeline. The PD market gives preference to the first-in-class therapies over the non-first-in-class ones, since, sespite the high attrition rate of
first-in-class products, the therapeutics that makes it to the market has much more potential of enhancing the PD treatment market than non-first-in-class
modes of therapy.
The PD therapeutics market offers huge opportunities for strategic alliances, as around 80 first-in-class products are in the development phase and have
not yet entered into any form licensing deals. Some first-in-class products are supported by promising clinical and scientific data, due to which deals
including such products will furnish huge growth opportunities for market players.
Browse the full Global Parkinson’s Disease Therapeutics Market report at http://www.mrrse.com/frontier-pharma-parkinsons-disease